by Dan Roberts February 3, 2010 Investigators at Kaiser Permanente Southern California in Pasadena reported in the February 2010 issue of Ophthalmology that Avastin and Lucentis performed equally in recent testing. In an indirect comparison of the two drugs, study author Dr. Donald Fong and coauthors reviewed the records of 452 patients treated for wet [Read More]
News
PEG-POD – New Gene Delivery Tool
by Dan Roberts January 2010 Researchers have developed a new tool for gene therapy that significantly increases gene delivery to cells in the retina compared to other carriers and DNA alone. The study was published in the January 2010 issue of The Journal of Gene Medicine by Tufts University School of Medicine and the Sackler [Read More]
Foresee Home Sets New Standard of Care for AMD Patients
by Dan Roberts Updated 3/1/2016 A relatively new technology, called preferential hyperacuity perimetry (PHP) allows eye doctors to detect progression in AMD sooner than with the Amsler grid. The key to the best outcome for treatment of wet AMD is early diagnosis and treatment. The ForeseeHomeª AMD Monitor by Notal Vision is approved by the [Read More]
Blue Light Filtering IOLs May Slow AMD
by Dan Roberts November 2009 A 2009 study* has shown that implantation of a blue light-filtering intraocular lens (IOL) at the time of cataract surgery increases macular pigment in the retina. This increase may provide protection against the development and/or progression of AMD. The study was reported by the Macular Pigment Research Group at the [Read More]
Brachytherapy May Reduce Burden of Treatment and Further Improve Visual Acuity
(Updated August 26, 2020) San Francisco, CA (PRWEB) October 27, 2009 — NeoVista, Inc. made public at the American Academy of Ophthalmology meeting the company’s interim study results from the preliminary study MERITAGE-I. The study was designed to examine the company’s novel epimacular brachytherapy procedure when used in patients that require chronic anti-VEGF treatment for [Read More]